Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New web tool aims to simplify genetic testing decisions for prostate cancer patients

NCT ID NCT04447703

Knowledge-focused Sponsor: Thomas Jefferson University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a mobile-friendly web tool that educates men with prostate cancer about genetic testing. Researchers compared traditional genetic counseling with the online tool to see if it helps patients decide whether to get tested. The study involved 346 men with advanced or high-risk prostate cancer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
web-based genetic education tool and genetic counseling
What this could lead to
If successful, this could make genetic testing information more accessible for men with prostate cancer, helping them make informed decisions.
What could go wrong
This is a completed study focused on user testing and decision-making, not on treatment outcomes. The tool may not change actual testing rates or health results.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

346 people

The number who actually took part.

Started

Aug 2020

Finished

Sep 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * AIM 1: Medical oncologists, radiation oncologists and urologists spanning Veterans Affairs (VA), academic, and community settings * AIM 2: Any English speaking man \>= 18 with PCA who has computer and web-access and meets any one of the following: * Metastatic disease * T3a or higher * Prostate specific antigen (PSA) \> 20 * Grade group 4 or higher * Intraductal or cribriform histology * Biochemical recurrence * Ashkenazi Jewish ancestry * Family history criteria (see below) \*\* Family history: If any one of the following levels are met, the person is eligible: * Level 1: \>= 1 close blood relative (first degree relative \[FDR\], second degree relative \[SDR\], third degree relative \[TDR\]) diagnosed with breast cancer =\< age 50 or the following cancers at any age: pancreatic, ovarian, or metastatic or intraductal/cribriform prostate cancer * Level 2: \>= 2 close blood relatives (FDR, SDR, TDR) on same side of the family with breast or prostate cancer at any age * Level 3: one brother, father, or \>= 2 family members (close blood relatives - FDR, SDR, TDR) on the same side of the family diagnosed with prostate cancer at \< 60 * Level 4: \>= 3 cancers on the same side of the family (especially if diagnosed =\< 50): bile duct, breast, colorectal, endometrial, gastric, kidney, melanoma, ovarian, pancreatic, prostate (grade groups 2-5 if known), small bowel, or urothelial Exclusion Criteria * Age \< 18 years * Mental or cognitive impairment that interferes with ability to provide informed consent * Non-English speaking * Having had prior germline genetic testing for inherited cancer risk (pertains to aim 2)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Biochemically recurrent prostate carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Biochemically recurrent prostate carcinoma Metastatic prostate carcinoma Stage IIIB prostate cancer ajcc V8 Stage IIIC prostate cancer ajcc V8 Stage IV prostate cancer ajcc V8

Contacts and locations

Locations

  • Associated Medical Professions of New York

    Syracuse, New York, 13210, United States

  • New York University- Langone Health

    New York, New York, 10016, United States

  • Sidney Kimmel Cancer Center at Thomas Jefferson University

    Philadelphia, Pennsylvania, 19107, United States

  • University of Washington/ SCCA

    Seattle, Washington, 98109, United States

  • VA New York Harbor Health System- Manhattan Campus

    New York, New York, 10010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.